期刊
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
卷 36, 期 1, 页码 12-17出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/YIC.0000000000000331
关键词
antipsychotic-induced constipation; bowel obstruction; clozapine; constipation; edema; ileus; laxatives; lubiprostone; serious mental illness
Antipsychotic-induced constipation is a treatment-limiting side effect for patients with serious mental illness. The FDA recently issued enhanced warnings about the serious, sometimes fatal, complications associated with constipation caused by clozapine. Despite the lack of FDA-approved agents for this specific indication, healthcare providers may seek alternative means to prevent and treat this condition, although off-label prescribing of newer medications presents unknown risks.
Antipsychotic-induced constipation is a treatment-limiting side effect for patients with serious mental illness (SMI). In addition to increased risk of constipation, due to adverse medication effects, individuals diagnosed with SMI are also prone to lifestyle factors that contribute to this medical complication. The USA Food and Drug Administration (FDA) recently released enhanced warnings about the risk of serious, sometimes fatal, complications associated with constipation caused by the antipsychotic, clozapine. It is likely this heightened warning will prompt providers to seek additional means to prevent and treat antipsychotic-induced constipation, despite having no agent with FDA approval for this specific indication. Off-label prescribing of newer medications for the treatment of antipsychotic-induced constipation is associated with risks, many of which are still unknown, considering the exclusion of patients with SMI in studies measuring nonpsychiatric outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据